GI & Endoscopy

Myron Falchuk, MD, of the Boston Endoscopy Center and an AmSurg partner, was recently chronicled in Jerome Groopman, MD's book How Doctors Think.

Here are 16 statistics on the prevalence, care and mortality associated with inflammatory bowel disease including Crohn's disease, ulcerative colitis and irritable bowel syndrome, according to the National Digestive Diseases Information Clearinghouse.

The American Gastroenterological Association, American College of Gastroenterology and American Society for Gastrointestinal Endoscopy have announced a joint commitment to combat the Centers for Medicare and Medicaid 2014 Medicare reimbursement cuts to upper GI/endoscopy services.

Here are issues that have had a significant impact on the field of gastroenterology in 2013, according to Medscape's Top 10 Practice Changers in Gastroenterology: 2013 report.

The American Society for Gastrointestinal Endoscopy recently penned a letter to the U.S. Senate Committee on Finance and Ways and Means Committee in support of repealing the sustainable growth rate formula.

Here are 18 statistics on gastroenterologist compensation by geographic area in 2012 in comparison to 2011, according to Medscape's Gastroenterologist Compensation Report: 2013 and Gastroenterologist Compensation Report: 2012.

Here are nine statistics on the digestive disease in the U.S., resulting care and associated costs, according to the National Digestive Diseases Information Clearinghouse.

The Kaiser Permanente Division of Research in Oakland, Calif., recently published a study in The Journal of the American Medical Association examining the connection between proton pump inhibitor and histamine 2 receptor antagonist use and malabsorption of vitamin B12.

The American Gastroenterological Association has released new guidelines for inducing and maintaining remission in Crohn's disease.

Takeda Pharmaceuticals has announced that the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the FDA have recommended approval for the company's biologic vedolizumab as a treatment for Crohn's disease and ulcerative colitis.